WellSky Launches Partnership with uMed

OVERLAND PARK, Kansas—WellSky and uMed announced a new partnership that expands patient access to national clinical research registries—longitudinal programs that track real-world patient outcomes and experience—by enabling homecare patients to participate in clinical studies from their home. 

“By combining the WellSky network of more than 10,000 home-based care organizations with uMed’s automated registry platform, the collaboration creates a scalable model for collecting high-quality real-world clinical information from patients—particularly underserved, rural and aging populations—who want to participate in clinical research, with no disruption to their routine or care,” the companies said in a released statement.

Pairing the WellSky provider network and the uMed ACCESS Cohorts platform, WellSky said the partnership will enable patients to join national research registries remotely. These registries are designed to collect real-world evidence on patient experiences, treatment preferences and medication usability across a range of therapeutic areas, including Parkinson’s disease, cardiometabolic conditions and autoimmune disorders.

“Access to participate in clinical research has historically been limited for many patients, particularly those not connected to major academic medical centers,” said Bill Miller, chairman and CEO of WellSky. “By integrating WellSky’s expansive provider network with uMed’s turnkey registry infrastructure, we are establishing a new framework for inclusive, patient-centered research that meets individuals where they are.”

“uMed’s mission is to make research more accessible and representative,” said Matt Wilson, founder and CEO of uMed. “Partnering with WellSky allows us to reach patients where they are—at home—while ensuring the process is seamless for clinical teams. Together, we’re expanding the potential of real-world evidence generation at scale from patient populations that have historically been out of reach.”

The initiative will begin with cardiometabolic and Parkinson’s cohorts in 2026, with plans to expand into additional therapeutic areas.